

UAS FAQs

Who is United Allergy Services?

United Allergy Services (UAS) is a medical services company that specializes in providing fully-staffed and operational allergy centers inside providers' offices. UAS manages the functional aspects of an allergy center and primary care providers manage the clinical side.

Who does UAS work with?

UAS brings effective and convenient allergy testing and immunotherapy to primary care providers; pulmonologists; ENT providers; pediatricians; internal medicine providers; and healthcare systems that treat the vast majority of patients with seasonal and perennial allergies.

What does UAS do?

UAS exists to empower qualified providers to advance the understanding of immunotherapy (IT) as the only known disease-modifying treatment for allergies. UAS uses skin (prick) testing as the best way to determine with precision the allergy a patient is suffering from.

What is immunotherapy?

Immunotherapy (IT) is a series of injections of customized allergy extracts administered over a period of years in order to suppress the body's reaction to a specific allergen. IT has been proven to reduce pharmacy, outpatient and health care costs, while decreasing the development of new sensitivities and reducing the progression of asthma in children.

Does it work?*

- 95% of patients had improved allergic rhinitis scores
- 82% of patients reported diminished use of medications
- 88% of patients reported improved Rhinoconjunctivitis Quality of Life Questionnaire scores after IT
- 86% would recommend allergy testing and immunotherapy to friends and family
- 82% feel comfortable administering immunotherapy injections
- 85% of people treated with IT for hay fever may achieve symptom relief within the first year of starting immunotherapy
- After 3-5 years of complete IT treatment, most patients experience little or no allergy symptoms

Is it safe?

More than 10 million allergy tests have been conducted and 14 million IT treatments have been administered—83% of those being done in the patient's home. IT is a proven, safe treatment and UAS has treated 115,000 patients (which equals to more than 15 million injections).

What is the UAS Systemic Reaction Rate vs. allergists?

UAS Systemic Reaction Rate for home immunotherapy is 0.16% compared to the allergist rate of 4-7%. Rush therapy is an even higher rate at 34%.*

UAS tests for what kind of allergies?

UAS test for the 48 most common seasonal and perennial allergens (such as mold, airborne, dust mite, cat and cockroach) in your geographic location.

What percentage of UAS patients on immunotherapy are pediatric patients (2-17 years of age)?

23% of UAS patients are pediatric patients.

How many providers are partnered with UAS?

There are over 2,600 practitioners that provide the allergy service line throughout 25 states.

How does UAS operate?

Request an implementation chart from us to show how we prepare your practice for allergy testing and IT treatment.

What are the billing procedures and what insurance carriers reimburse for the UAS allergy line?

The practice completes their billing procedures as normal. All reimbursements and copays are paid directly to the practice and UAS will invoice the practice for contracted service fees. Most major commercial plans and government plans reimburse for the two CPT codes for: skin (prick) test and mixing of immunotherapy on site.

**Sources:*

Allergen immunotherapy: A practice parameter third update. Linda Cox, M.D., Harold Neson, M.D. and Richard Lockey, M.D. American Academy of Allergy, Asthma & Immunology. September 23, 2010.

Frederick M. Schaffer, M.D., Lisa Welchel, FNPC, Hope Soliz, Tim Crimmins, Myla Ebeling, PhD, Tom Hulse, PhD, Larry Garner, CPT, BA, . "The Safety of Home Immunotherapy Utilizing the United Allergy Services Protocol. Manuscript in preparation. (2012)

American College of Allergy, Asthma and Immunology. Allergy treatment. Available at: <http://acaai.org/allergist/allergies/Treatment/Pages/default.aspx>. Accessed February 1, 2011.

National Institute of Allergy and Infectious Disease. Airborne allergens. Something in the air. NIH Publication No. 03-7045. Available at: http://www.niaid.nih.gov/topics/allergic_diseases/documents/airborne_allergens.pdf. Accessed February 1, 2011.

Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol. 2002;109:251-256.